National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): all 100 studies

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• Pain Phenotyping of Rheumatic Diseases - An Observational StudyNot yet recruitingNCT07829497
• Natural History of Inflammatory Muscle DiseasesRecruitingNCT05738824
• Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by QuestionnairesRecruitingNCT05567198
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVDRecruitingNCT05440422Phase 2
• Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related ConditionsRecruitingNCT03510442
• Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic DiseaseRecruitingNCT02504879
• Studies of Dermatologic Diseases Biospecimen Acquisition ProtocolRecruitingNCT02471352
• Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic VasculitisRecruitingNCT02257866
• Effects of Treatments on Atopic DermatitisRecruitingNCT01631617Phase 2
• Natural History and Development of SpondyloarthritisRecruitingNCT01422694
• Studies of the Natural History of Rheumatic DiseasesRecruitingNCT00024479
• Study of Systemic Lupus ErythematosusRecruitingNCT00001372
• Genomic Effects of Glucocorticoids in Patients With Systemic Lupus ErythematosusCompletedNCT04233164Early Phase 1Results posted
• Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT03395340Phase 2Results posted
• Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)CompletedNCT02338999Phase 1/2Results posted
• Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)CompletedNCT01801449Phase 2Results posted
• Anakinra for Inflammatory Pustular Skin DiseasesCompletedNCT01794117Phase 2Results posted
• Anakinra for Behcet s DiseaseCompletedNCT01441076Phase 1/2Results posted
• Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's ArteritisCompletedNCT00556439Phase 2Results posted
• Interleukin-1 Trap to Treat Autoinflammatory DiseasesCompletedNCT00094900Phase 2Results posted
• Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory DiseaseTerminatedNCT00069329Phase 1/2Results posted
• Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile DermatomyositisWithdrawnNCT07012057Phase 2
• A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or LupusWithdrawnNCT06238531Phase 1
• Natural History and Pathogenesis of Alopecia in Children and AdultsCompletedNCT05502796
• Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune DiseasesCompletedNCT04690816
• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus ErythematosusCompletedNCT02535689Phase 1
• Frequency and Complications of Major Orthopedic Procedures in Medicare BeneficiariesActive, not recruitingNCT02281747
• Omalizumab for LupusCompletedNCT01716312Phase 1
• Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) StudyCompletedNCT01360099
• A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's DiseaseWithdrawnNCT01211977Phase 1/2
• Consortium for the Longitudinal Evaluation of African Americans With Early Rheumatoid Arthritis (The CLEAR Registry)CompletedNCT00815425
• Insulin Resistance and Atherosclerosis in Women With LupusCompletedNCT00544102
• The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle DiseaseStatus unknownNCT00457314Phase 2
• A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of PhototoxicityCompletedNCT00353158Phase 1
• Juvenile Rheumatoid Arthritis Research RegistryCompletedNCT00090571
• Progression of Spinal Fusion in Ankylosing SpondylitisCompletedNCT00085995
• Genetics of Ankylosing SpondylitisCompletedNCT00081562
• Osteoarthritis Initiative (OAI): A Knee Health StudyCompletedNCT00080171
• Protective Brace to Prevent Hand and Arm InjuriesCompletedNCT00074893Not applicable
• National Registry for Ichthyosis and Related DisordersCompletedNCT00074685
• Scleroderma RegistryCompletedNCT00074568
• Registry for African Americans With Early Rheumatoid ArthritisCompletedNCT00074555
• Genetics of FibromyalgiaStatus unknownNCT00071162
• Electromagnetic Treatment For Bone Loss After Forearm FractureCompletedNCT00067834Phase 1/2
• Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or SulfasalazineCompletedNCT00062465Phase 2
• Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile DermatomyositisCompletedNCT00059748
• Gabapentin in Fibromyalgia Trial (GIFT)CompletedNCT00057278Phase 2/3
• Genetic Determinants of Ankylosing Spondylitis SeverityCompletedNCT00056849
• Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal StudyCompletedNCT00056719
• Clinically Important Changes in Rheumatoid ArthritisCompletedNCT00056602
• Monoclonal Antibody Treatment for Systemic Lupus ErythematosusCompletedNCT00046774Phase 1
• Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal WomenCompletedNCT00043719Phase 3
• Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus ErythematosusCompletedNCT00042523
• Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma PatientsTerminatedNCT00040651Phase 1
• Effects of Exercise Poles on Older Adults During Exercise WalkingCompletedNCT00037167Phase 1/2
• The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With EtanerceptCompletedNCT00034060Phase 2
• Infliximab (Remicade ) to Treat Dermatomyositis and PolymyositisCompletedNCT00033891Phase 2
• Blood Component Collection From Patients With Rheumatic or Kidney Disease and Healthy VolunteersTerminatedNCT00031174
• Positron Emission Tomography (PET) to Locate Areas of White Blood Cell ActivityCompletedNCT00029926
• Infliximab to Treat Children With Juvenile Rheumatoid ArthritisTerminatedNCT00029042Phase 2
• Isotretinoin in Preventing Skin CancerCompletedNCT00025012Not applicable
• Prevention of Steroid-Induced Osteoporosis in ChildrenTerminatedNCT00022841Phase 1/2
• 3-D Laser Imaging to Analyze Neck MovementStatus unknownNCT00022828
• Management of Compartment Syndrome With UltrafiltrationCompletedNCT00022815Phase 1
• Image Guided System for Orthopaedic SurgeryTerminatedNCT00022802Phase 2
• Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis PatientsCompletedNCT00014794Phase 1
• Humanized LL2IGG to Treat Systemic Lupus ErythematosusCompletedNCT00011908Phase 1
• Treatment of Psoriasis With Parathyroid HormoneCompletedNCT00007306Phase 1/2
• Scalp Psoriasis Treatment With a Fiber Optic CombCompletedNCT00007293Phase 1/2
• Muscle Strengthening Device for Knee OsteoarthritisCompletedNCT00007241Phase 2
• Study of Arthritis and Related ConditionsCompletedNCT00006333
• Infliximab for the Treatment of Early Rheumatoid ArthritisCompletedNCT00006292Phase 2
• High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV CyclophosphamideCompletedNCT00005778Phase 3
• Oral Type I Collagen for Relieving SclerodermaCompletedNCT00005675Phase 2
• Safety and Effectiveness of h5G1.1-mAb for DermatomyositisCompletedNCT00005571Phase 2
• Etanercept for Wegener's GranulomatosisCompletedNCT00005007Phase 2/3
• BG9588 (Anti-CD40L Antibody) to Treat Lupus NephritisCompletedNCT00001789Phase 2
• Genetic Basis of Primary ImmunodeficienciesTerminatedNCT00001788
• Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis PatientsCompletedNCT00001679
• Genetics of Rheumatoid ArthritisCompletedNCT00001678
• Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and EfficacyCompletedNCT00001677Phase 2
• Cyclophosphamide and Fludarabine to Treat Lupus NephritisCompletedNCT00001676Phase 1
• Evaluation and Treatment of Patients With Dermatologic DiseasesCompletedNCT00001506
• The Acquisition of Blood and Skin Samples From Normal Volunteers to Support Research Activities on Dermatologic DiseasesCompletedNCT00001505
• A Controlled Trial of Intermittent Fludarabine for Psoriatic ArthritisCompletedNCT00001422Phase 2
• Methimazole to Treat Polymyositis and DermatomyositisCompletedNCT00001421Phase 2
• Study of Psoriatic ArthritisCompletedNCT00001420
• Steroid Hormones, TH1/TH2 Cytokines and Reproductive StatusCompletedNCT00001376
• The Pathogenesis of Inflammatory Synovitis: A Study of Early ArthritisCompletedNCT00001375
• Genetic and Family Studies of Inherited Muscle DiseasesCompletedNCT00001331
• Study of Silicone-Associated Connective Tissue DiseasesCompletedNCT00001330
• Genetic and Immune Studies of Rheumatoid Arthritis and Related ConditionsCompletedNCT00001291
• Study and Treatment of Inflammatory Muscle DiseasesCompletedNCT00001265
• Improving Functional Recovery After Hip FractureCompletedNCT00000436Phase 3
• dnaJ Peptide for Relieving Rheumatoid ArthritisCompletedNCT00000435Phase 2
• Impact of Exercise on Older Persons With OsteoarthritisCompletedNCT00000434Phase 2
• Blocking Tumor Necrosis Factor in Ankylosing SpondylitisCompletedNCT00000433Phase 2
• Low-Dose Hormone Replacement Therapy and Alendronate for OsteoporosisTerminatedNCT00000430Phase 3
• Tidal Lavage in Knee OsteoarthritisCompletedNCT00000424Phase 2
• Osteoporosis Prevention in Preadolescent GirlsCompletedNCT00000413Phase 2

← National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) overview and focus areas